Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 11/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31450809 | 1.00 | BCL2 (0.68) | BCL2ADRA1DDRD3SLC6A3TMEM97 | |
| SCHEMBL31450985 | 0.94 | BCL2 (0.68) | BCL2ADRA1DDRD3SLC6A3TMEM97 | |
| SCHEMBL26648189 | 0.94 | BCL2 (0.68) | BCL2ADRA1DDRD3SLC6A3TMEM97 | |
| SCHEMBL26647748 | 0.94 | BCL2 (0.66) | BCL2ADRA1DDRD3SLC6A3TMEM97 | |
| SCHEMBL31450757 | 0.94 | BCL2 (0.66) | BCL2ADRA1DDRD3SLC6A3TMEM97 | |
| SCHEMBL33532756 | 0.94 | BCL2 (0.66) | BCL2ADRA1DDRD3SLC6A3TMEM97 | |
| SCHEMBL26648376 | 0.93 | BCL2 (0.66) | BCL2 | |
| SCHEMBL31450753 | 0.93 | BCL2 (0.67) | BCL2 | |
| SCHEMBL26647768 | 0.93 | BCL2 (0.67) | BCL2 | |
| SCHEMBL31450911 | 0.92 | BCL2 (0.65) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | BCL2 4/4885ADRA1D 2233/4885DRD3 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.